Orange Book product · Generic (ANDA)
EPTIFIBATIDE
EPTIFIBATIDE
At a glance
Mar 07, 2018
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 07, 2018
8 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
EPTIFIBATIDE
Strength
2MG/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 204693
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of EPTIFIBATIDE
- 1998INTEGRILINBrand (NDA)
NDA 020718 · MSD SUB MERCK
- 2024EPTIFIBATIDEGeneric (ANDA)
ANDA 213599 · MEITHEAL
- 2021EPTIFIBATIDEGeneric (ANDA)
ANDA 213081 · SHUANGCHENG
- 2020EPTIFIBATIDEGeneric (ANDA)
ANDA 207864 · HYBIO
- 2019EPTIFIBATIDEGeneric (ANDA)
ANDA 204361 · USV
- 2019EPTIFIBATIDEGeneric (ANDA)
ANDA 204362 · USV
- 2019EPTIFIBATIDEGeneric (ANDA)
ANDA 209864 · SLATE RUN PHARMA
- 2018EPTIFIBATIDEGeneric (ANDA)
ANDA 208554 · BAXTER HLTHCARE CORP
- 2018EPTIFIBATIDEGeneric (ANDA)
ANDA 203258 · MYLAN LABS LTD
- 2017EPTIFIBATIDEGeneric (ANDA)
ANDA 205557 · ACCORD HLTHCARE
- 2017EPTIFIBATIDEGeneric (ANDA)
ANDA 204589 · RISING
- 2016EPTIFIBATIDEGeneric (ANDA)
ANDA 205581 · AMNEAL PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
